Skip to main content

FDA Approvals

FDA Approvals, Lung Cancer, Oncology

Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma

FDA Approvals, Prostate Cancer

Lynparza First Targeted Therapy Approved for Metastatic Prostate Cancer with HRR Mutation

FDA Approvals, Lung Cancer, Oncology

Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression

FDA Approvals, Lung Cancer, Oncology

Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC

Tabrecta First FDA-Approved Targeted Therapy for Metastatic NSCLC and MET Exon 14 Skipping

Retevmo First Therapy Approved for 3 Types of Cancers with RET Mutations

FDA Approves New 400 mg Every-6-Weeks Dosing Regimen of Keytruda for All Indications

Zejula First PARP Inhibitor Approved as First-Line Maintenance Treatment for All Patients with Ovarian Cancer

FDA Approves Darzalex Faspro as Subcutaneous Formulation for All Patients with Multiple Myeloma

FDA Approvals, Urothelial Cancer, Oncology

Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer

Page 17 of 53
Results 161 - 170 of 524